Drug Profile
Research programme: gene therapies - Synpromics/University College London
Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Synpromics
- Developer Synpromics; University College London
- Class Antiparkinsonians; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for research development in Parkinson's-disease in United Kingdom
- 13 Aug 2019 Synpromics has been acquired by Asklepios BioPharmaceutical
- 25 Jan 2018 Synpromics signs research and development agreement with UCL Great Ormond Street Institute of Child Health for development of gene therapies in treatment of pathologies affecting haematopoetic system